Immuneering FY2026 Earnings Forecast Cut by HC Wainwright

Key Points

• HC Wainwright cut its FY2026 earnings forecast for Immuneering to a loss of $1.24 per share from $1.10, below the current consensus estimate of a $1.09 loss, while maintaining a Buy rating.
• Immuneering reported a third-quarter loss of $0.37 per share, missing analyst expectations of a $0.31 loss. The stock opened at $3.49, near its 52-week low of $3.38.
• Analyst sentiment remains mixed but leans positive: the stock has a consensus “Moderate Buy” rating and a $15.67 price target, despite HC Wainwright’s more pessimistic loss projections through 2030.

Immuneering Corporation (NASDAQ:IMRX - Free Report) - HC Wainwright lowered their FY2026 earnings estimates for Immuneering in a note issued to investors on Friday, October 30th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($1.24) for the year, down from their prior estimate of ($1.10). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Immuneering's current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Immuneering's Q4 2026 earnings at ($0.39) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.48) EPS, FY2027 earnings at ($1.78) EPS, FY2028 earnings at ($1.87) EPS, FY2029 earnings at ($1.86) EPS and FY2030 earnings at ($0.81) EPS.

A number of other research analysts have also commented on the stock. Chardan Capital upgraded shares of Immuneering to a "strong-buy" rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a report on Monday, September 21st. Wall Street Zen downgraded shares of Immuneering from a "hold" rating to a "sell" rating in a research note on Monday, July 20th. UBS Group set a $14.00 price target on Immuneering in a report on Thursday, August 6th. Finally, Needham & Company LLC raised their price target on Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.67.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $3.49 on Tuesday. The stock has a market cap of $225.79 million, a P/E ratio of -3.39 and a beta of 0.46. The firm has a fifty day moving average price of $4.25 and a 200 day moving average price of $4.79. Immuneering has a 1-year low of $3.38 and a 1-year high of $8.48.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.06).

Institutional Trading of Immuneering

Several hedge funds and other institutional investors have recently made changes to their positions in IMRX. PVG Asset Management Corp purchased a new stake in Immuneering in the 1st quarter valued at approximately $773,000. Weiss Asset Management LP acquired a new position in Immuneering during the 1st quarter worth approximately $464,000. Hsbc Holdings PLC acquired a new position in Immuneering during the 1st quarter worth approximately $198,000. Levin Capital Strategies L.P. purchased a new position in shares of Immuneering during the 1st quarter worth approximately $53,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Immuneering during the 1st quarter worth approximately $75,000. Hedge funds and other institutional investors own 67.65% of the company's stock.

Immuneering News Roundup

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating, indicating the analyst continues to see long-term upside potential in Immuneering’s pipeline and business prospects.
• Positive Sentiment: Wall Street’s overall view remains constructive, with analysts rating the stock a “Moderate Buy.” Immuneering Corporation Stock Rated Moderate Buy by Wall Street Analysts
• Neutral Sentiment: HC Wainwright projected quarterly losses of $0.41 per share in Q1 2027, $0.43 in Q2, $0.45 in Q3 and $0.48 in Q4. The firm forecasts a full-year 2027 loss of $1.78 per share, followed by losses of $1.87 in 2028 and $1.86 in 2029.
• Negative Sentiment: HC Wainwright reduced its Q4 2026 loss estimate to $0.39 per share from $0.32 and lowered its FY2026 forecast to a $1.24 loss from $1.10. These revisions are worse than the current consensus estimate of a $1.09 full-year loss.
• Negative Sentiment: Longer-term estimates were also cut substantially: FY2027 to a $1.78 loss from $1.22, FY2028 to $1.87 from $1.30, FY2029 to $1.86 from $1.32, and FY2030 to an $0.81 loss from $0.40. The more pessimistic outlook likely contributed to the stock’s decline.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering's lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.